AMRX Amneal Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1723128 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.9%
TTM net income YoY2,159.3%
TTM EPS YoY3,900.0%
Revenue 3-yr CAGR10.2%
Net income 3-yr CAGR270.1%
Margins
Gross margin40.2%
Operating margin15.0%
Net margin4.2%
FCF margin2.8%
EBITDA margin—
Returns
ROE63.2%
ROA3.0%
ROIC (approx.)16.3%
Asset turnover0.72x
Leverage & solvency
Liabilities / assets87.8%
Debt / equity5.53x
Current ratio1.87x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.36x
Accruals ratio-1.1%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B |
| Cost of revenue | $1.91B | $1.77B | $1.57B | $1.43B | $1.32B |
| Gross profit | $1.11B | $1.02B | $820.57M | $784.71M | $768.97M |
| R&D expense | $186.18M | $190.71M | $163.95M | $195.69M | $201.85M |
| SG&A expense | $526.83M | $476.44M | $429.68M | $399.70M | $365.50M |
| Operating income | $394.10M | $249.33M | $204.37M | -$94.93M | $152.72M |
| Pretax income | $139.21M | -$55.01M | -$40.27M | -$248.13M | $31.37M |
| Income tax | $11.28M | $18.86M | $8.45M | $6.66M | $11.20M |
| Net income | $72.06M | -$116.89M | -$83.99M | -$270.58M | $13.16M |
| EBITDA | $451.40M | $311.93M | $270.57M | -$26.83M | $213.42M |
| EPS (basic) | 0.23 | -0.38 | -0.48 | -0.86 | 0.07 |
| EPS (diluted) | 0.22 | -0.38 | -0.48 | -0.86 | 0.07 |
| Weighted avg. shares (diluted) | 324.81M | 308.98M | 176.14M | 150.94M | 151.82M |
| Balance sheet | |||||
| Cash & equivalents | $282.03M | $118.42M | $91.54M | $35.23M | $256.74M |
| Receivables | — | — | — | $741.79M | $662.58M |
| Inventory | $606.30M | $612.45M | $581.38M | $530.74M | $489.39M |
| Current assets | $1.91B | $1.59B | $1.38B | $1.41B | $1.52B |
| PP&E, net | $442.95M | $424.91M | $447.57M | $469.81M | $514.16M |
| Goodwill | $595.47M | $597.44M | $598.63M | $598.85M | $593.02M |
| Intangibles | $563.50M | $732.38M | $890.42M | $1.10B | $1.17B |
| Total assets | $3.68B | $3.50B | $3.47B | $3.80B | $3.94B |
| Current liabilities | $881.63M | $1.13B | $846.60M | $752.80M | $677.24M |
| Short-term debt | $6.76M | $224.21M | $34.12M | $29.96M | $30.61M |
| Long-term debt | $2.57B | $2.16B | $2.39B | $2.59B | $2.68B |
| Total debt | $2.57B | $2.39B | $2.42B | $2.62B | $2.71B |
| Total liabilities | $3.67B | $3.55B | $3.41B | $3.59B | $3.56B |
| Shareholders' equity | -$70.79M | -$109.27M | $19.78M | $298.42M | $360.34M |
| Net debt | $2.29B | $2.27B | $2.33B | $2.59B | $2.45B |
| Cash flow statement | |||||
| Operating cash flow | $339.99M | $295.10M | $345.58M | $65.10M | $241.82M |
| Capital expenditure | $70.06M | $51.92M | $43.22M | $46.41M | $47.73M |
| Free cash flow | $269.93M | $243.18M | $302.36M | $18.69M | $194.09M |
| Investing cash flow | -$112.26M | -$63.00M | -$69.19M | -$174.31M | -$194.18M |
| Financing cash flow | -$31.53M | -$211.79M | -$212.57M | -$106.62M | -$138.12M |
| Depreciation & amortization | $57.30M | $62.60M | $66.20M | $68.10M | $60.70M |
| Stock-based compensation | $31.95M | $27.77M | $26.82M | $31.85M | $28.41M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.